Welcome to the 2026 Annual Meeting of Editas Medicine stockholders. I would now like to introduce Jessica Hopfield, Chair of the Board. Good morning. Welcome to the 2026 Annual Meeting of Stockholders of Editas Medicine. I am Jessica Hopfield, Chair of the Board, and I will be presiding over this meeting. At this time, I call the meeting to order. We are pleased to have everyone join this live webcast of our annual meeting, which is being held in an all-virtual format. We have designed this meeting to provide stockholders the same rights and opportunities to participate as they would have at an in-person meeting. Before we get to the formal business of the meeting, I would like to make some introductions. Present at the meeting today are Bernadette Connaughton, Andrew Hirsch, Dr. Elliott Levy, and Dr. David Scadden, each a director of Editas Medicine. In addition, I am pleased to be joined by our President and Chief Executive Officer, Dr. Gilmore O'Neill, who is also a director, and the other members of senior management, Dr. Linda C. Burkly, our Chief Scientific Officer, Damien Grierson, our General Counsel, Amy Parison, our Chief Financial Officer, and other leaders. I would also like to introduce Holly Reeves, a representative from PricewaterhouseCoopers, our independent registered public accounting firm, and Terry Cassett, who will be serving as our Inspector of Election. After we complete the formal part of the meeting, Gilmore O'Neill will provide some remarks on behalf of the company. Then we will take questions. In order to conduct an orderly meeting, I call your attention to the rules of conduct posted on the virtual meeting website, which include information about participating in the meeting, including asking questions. I have received an affidavit from the company's proxy solicitor, Broadridge Financial Solutions, certifying that the notice of the annual meeting and proxy statement were sent to all stockholders of record as of April 20th, 2026. This affidavit is available for inspection by any stockholder. Our first order of business at this meeting is to determine whether the shares represented at this meeting, either in person, via this annual meeting, or by proxy, are sufficient to constitute a quorum for the purpose of transacting business. The Inspector of Election has informed me that there are present at this meeting, either in person or by proxy, a majority of outstanding shares of common stock entitled to vote. I declare that a quorum exists. Turning now to the items to be voted on at this meeting, as indicated in the notice of meeting and accompanying documents that were sent to shareholders. The first matter to be voted on is the election of two Class I directors to serve until the 2029 annual meeting of shareholders and until their successors are duly elected and qualified. The two nominees for election are Bernadette Connaughton and Elliott Levy, MD. The second matter to be voted on is the advisory vote to approve named executive officer compensation. The proxy statement for this meeting contained a text of the resolution that stockholders are asked to approve. The final matter to be voted on is the ratification of the selection of PricewaterhouseCoopers, LLP as the company's registered public accounting firm for the fiscal year ending December 31st, 2026. If there are any questions on the proposals, they may be submitted on the virtual meeting website. If asking a question, please include your name and affiliation with the company. We will pause briefly to allow the submission of any questions on the proposals. Seeing no questions about the proposals, we'll move on to voting on the proposals. Seeing that there are no further questions, we will move on to voting on the proposals. I hereby declare that the polls are now open for each matter to be voted on today. If you have not yet voted or you previously voted by proxy and wish to change your vote, you may vote by clicking the "Vote Here" button on the virtual meeting website and follow the instructions there. We will pause briefly to allow stockholders to vote. Now that everyone has had an opportunity to vote, the business items on the agenda for this meeting are complete, and the polls are now closed. Terry Cassett, the Inspector of this election, will prepare a final report that will be filed with the minutes of this meeting. Based on the preliminary results, each of the nominees for director has been elected as a Class I director. The advisory resolution approving named executive officer compensation has been approved. The appointment of PricewaterhouseCoopers, LLP has been ratified. The final vote results will be included in the Form 8-K that will be filed within four business days after this meeting. As there is no further business to come before the meeting, I declare the formal part of this meeting adjourned. At this time, I would like to ask Damien Grierson to provide a reminder regarding certain forward-looking statements that we may make, following which Gilmore O'Neill will provide some remarks regarding the company. After the remarks, the members of the company's management will answer any appropriate questions from the stockholders. Thank you, Jessica. I would like to note that various remarks that we may make about future expectations, plans, and prospects for the company constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC and in other filings that the company may make with the SEC in the future. In addition, these forward-looking statements represent the company's expectations only as of today. While the company may elect to update these forward-looking statements, it specifically disclaims any obligation to do so. Any forward-looking statements should not be relied upon as representing the company's estimates or views as of any date subsequent to today. Now I turn it over to Gilmore. Thank you, Damien. Good morning, and thank you for joining us for the 2026 Editas Medicine virtual Annual Meeting of Stockholders. I am Gilmore O'Neill, President and CEO of Editas Medicine. At Editas, we are focused on developing transformative, durable, and accessible medicines that meaningfully improve people's lives. These objectives are highlighted by our lead asset, EDIT-401, an experimental one-time treatment designed to deliver deep, durable reductions in LDL cholesterol, or LDL-C, for hyperlipidemia, a key risk factor for cardiovascular disease. Cardiovascular disease remains a leading cause of death worldwide, and elevated LDL-C affects more than 70 million people in the United States alone. While existing therapies have improved outcomes, many patients still cannot achieve target LDL-C levels due to limited responses or challenges with tolerability and compliance. EDIT-401 is differentiated by a novel mechanism designed to upregulate the LDL receptor through precise editing of regulatory non-coding DNA with the potential to achieve LDL-C reductions beyond those achieved with current therapies. Recently, we reported preclinical data showing that a single dose of EDIT-401 achieved greater than 90% mean LDL-C reductions in non-human primates with durable lowering through approximately six months. We also observed approximately 90% mean reductions in ApoB and Lp(a), additional key cardiovascular risk factors. Additional data support a promising safety and delivery profile. Together, these findings support EDIT-401 as a potentially best-in-class, one-time therapy addressing multiple cardiovascular risk factors and drive our beliefs that EDIT-401 has the potential to change the treatment paradigm, delivering lifelong cardiovascular benefit. We also recently announced a public offering of up to $319.4 million to support advancement of EDIT-401 into the clinic, with plans to generate early human proof-of-concept data by year-end and top-line dose ranging data in 2027. This progress is driven by our proprietary editing technologies, advanced delivery capabilities, an exceptional scientific team, and all of our dedicated employees. Thank you for joining us today and for your continued interest in Editas Medicine. Thank you, Gilmore. At this time, I would like to ask Damien Grierson to help coordinate and announce questions. We will now begin the Q&A session. You can ask a question by submitting it in the Q&A section on your web console. Please submit any questions now. There are no questions at this time. Jessica, I turn the call back over to you. Thank you again for your continued dedication to the company. The annual stockholder meeting for Editas Medicine has now come to an end. Thank you for attending. You may now disconnect.